The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Lilly Oncology To Disclose New Pipeline Data At ASCO 2012

Monday, May 14, 2012

Lilly Oncology To Disclose New Pipeline Data At ASCO 201209:00 EDT Monday, May 14, 2012Updates on Three of Six Ongoing Phase III Ramucirumab Trials to Be PresentedINDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from several molecules that make up its clinical oncology pipeline during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from June 1 ? 5, 2012. Lilly Oncology has more than 30 molecules in early- and late-stage development to treat various types of cancer. The company remains committed to evaluating each of its molecules for biomarkers or genetic mutations that can help better identify the specific patients who will better respond to these medicines.   Early-Stage Pipeline ResultsLilly early-stage pipeline molecules will be featured at oral presentations at ASCO with two first-in-human Phase I studies, one on its oral NOTCH inhibitor LY900009 and the other for its oral p38 MAPK inhibitor LY2228820 dimesylate, both being evaluated in patients with advanced cancer. Another oral presentation will highlight LY2780301, an oral P70S6K/AKT inhibitor, a first-in-human Phase I study of patients with refractory solid tumors.Late-Stage Ramucirumab UpdatesLilly will also present several trials-in-progress posters representing a portion of the broad Phase III clinical development program for ramucirumab, a fully human IgG1 monoclonal antibody receptor antagonist designed to bind to the extracellular domain of vascular endothelial growth factor receptor-2 (VEGFR-2). Trial updates for ramucirumab will focus on its ongoing Phase III trials in metastatic colorectal cancer, metastatic gastric adenocarcinoma and hepatocellular cancer, as well as results of a Phase II study in persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.Ramucirumab represents one of the largest clinical programs currently underway at Lilly. Six global Phase III trials ? one each in breast, colorectal, hepatocellular and lung cancer, and two in gastric cancer ? are ongoing and patient enrollment milestones have recently been achieved in both the Phase III breast and gastric (monotherapy) cancer trials. "Lilly Oncology's clinical pipeline is one of the most diverse in the industry, including a mix of large and small molecules that target a broad range of cancers," said Richard Gaynor, M.D., vice president, product development and medical affairs for Lilly Oncology. "We believe that our broad oncology research and development program will lead to new therapies for a wide array of patients." Times and Locations of the Data Sessions:Ramucirumab (IMC-1121B)Abstract #5012: Poster Session: Friday, June 1, 2012, 1:00 PM - 5:00 PM A phase II, open-label, multicenter study of IMC-1121B (ramucirumab; RAM) monotherapy in the treatment of persistent or recurrent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal (PPC) carcinoma (CP12-0711/NCT00721162). Author/Speaker: Richard T. Penson Location: E450a; Poster Board 1Abstract #TPS3634: Trials in Progress Poster Session: Monday, June 4, 2012, 8:00 AM - 12:00 PM A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780). Author/Speaker: Axel Grothey Location: S Hall A2; Poster Board 38GAbstract #TPS4139: Trials in Progress Poster Session: Monday, June 4, 2012, 8:00 AM - 12:00 PM A randomized, multicenter, double-blind, placebo (PBO)-controlled phase III study of paclitaxel (PTX) with or without ramucirumab (IMC-1121B; RAM) in patients (pts) with metastatic gastric adenocarcinoma, refractory to or progressive after first-line therapy with platinum (PLT) and fluoropyrimidine (FP). Author/Speaker: Hansjochen Wilke Location: S Hall A2; Poster Board 53BAbstract #TPS4146: Trials in Progress Poster Session: Monday, June 4, 2012, 8:00 AM - 12:00 PM A multicenter, randomized, double-blind, phase III study of ramucirumab (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and BSC as second-line treatment in patients (pts) with hepatocellular carcinoma (HCC) following first-line therapy with sorafenib (SOR). Author/Speaker: Andrew X. Zhu Location: S Hall A2; Poster Board 54ANOTCH inhibitor (LY900009)Abstract #3008: Oral Abstract Session: Sunday, June 3, 2012, 12:15 PM - 12:30 PM A first-in-human phase I study of the oral Notch inhibitor LY900009 in patients with advanced cancer Author/Speaker: Shubham Pant Location: E Arie Crown Theaterp38 MAPK inhibitor (LY2228820 dimesylate)Abstract # 3001: Oral Abstract Session: Sunday, June 3, 2012, 10:00 AM ? 10:15 AM A first-in-human phase I study of the oral p38 MAPK inhibitor LY2228820 dimesylate in patients with advanced cancer. Author/Speaker: Matthew P. Goetz Location: E Arie Crown TheaterP70S6K/AKT inhibitor (LY2780301)Abstract # 3005: Oral Abstract Session: Sunday, June 3, 2012, 11:15 AM ? 11:30 AM First-in-human phase I study of LY2780301, an oral P70S6K/AKT inhibitor, in patients with refractory solid tumors. Author/Speaker: Emiliano Calvo Location: E Arie Crown TheaterP-LLYThis press release contains forward-looking statements about the potential of ramucirumab, LY900009, LY2228820 dimesylate and LY2780301 and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the products will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.(Logo:  http://photos.prnewswire.com/prnh/20031219/LLYLOGO)SOURCE Eli Lilly and CompanyFor further information: Media, Amy Sousa (Lilly), Office: +1-317-276-8478, Mobile: +1-317-997-1481; Neil Hochman (TogoRun), Office: +1-212-453-2067, Mobile: +1-516-784-9089